Bibliography:

1. ​ ‘longevity’ tag

2. ​ ‘GLP agonists (psych)’ tag

3. ​ ‘semaglutide’ tag

4. ​ ‘tirzepatide’ tag

5. ​ The benefits of GLP-1 drugs beyond obesity

6. ​ Drug release profile of a novel exenatide long-term drug delivery system (OKV-119) administered to cats

7. ​ Functional and multi-omic aging rejuvenation with GLP-1R agonism

8. ​ Trial of Lixisenatide in Early Parkinson’s Disease

9. ​ Is Target-Based Drug Discovery Efficient? Discovery and ‘Off-Target’ Mechanisms of All Drugs

10. ​ Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicenter, randomized, dose-response, phase 2 study

11. ​ Patents and Regulatory Exclusivities on GLP-1 Receptor Agonists

12. ​ Evaluation of Out-of-Pocket Costs and Treatment Intensification With an SGLT2 Inhibitor or GLP-1 RA in Patients With Type 2 Diabetes & Cardiovascular Disease

13. ​ Medicare Part D Coverage of Antiobesity Medications—Challenges and Uncertainty Ahead

14. ​ The Effects of Switching from Dipeptidyl Peptidase-4 Inhibitors to Glucagon-Like Peptide-1 Receptor Agonists on Bone Mineral Density in Diabetic Patients

15. ​ The Gut-Bone Axis in Diabetes

16. ​ Safety and efficacy assessment of a GLP-1 mimetic: insulin glargine combination for treatment of feline diabetes mellitus

17. ​ Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms

18. ​ The GLP-1 mimetic exenatide potentiates insulin secretion in healthy cats

19. ​ Normalization of fasting hyperglycemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients

20. ​ Effect of Truncated Glucagon-Like Peptide-1 [Proglucagon-(78-107) amide] on Endocrine Secretion from Pig Pancreas, Antrum, and Nonantral Stomach

21. ​ GLP-1 Receptor Agonists’ Impact on Cardio-Renal Outcomes and Mortality in T2D With Acute Kidney Disease

22. ​ Could Danuglipron Be the Next Ozempic in Pill Form?

23. ​ GLP-1 Receptor Agonists and Colorectal Cancer Risk in Drug-Naive Patients With Type 2 Diabetes, With and Without Overweight/Obesity

24. ​ Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 Diabetes

25. ​ Safety, Tolerability, and Proof-Of-Concept Study of OKV-119, a Novel Exenatide Long-Term Drug Delivery System, in Healthy Cats

26. ​ Doctors Test the Limits of What Obesity Drugs Can Fix

27. ​ 2023-frias-figure2-effectsoforforglipronforbloodsugarandweightlossintype2diabetes.jpg

28. ​ 2017-schneider.pdf

29. ​ https://edition.cnn.com/2024/05/08/health/ozempic-babies-pregnancy/index.html

30. ​ https://journals.sagepub.com/doi/full/10.1177/1098612X16660441

31. ​ https://marginalrevolution.com/marginalrevolution/2024/07/the-economics-of-glp-1.html

32. ​ https://onlinelibrary.wiley.com/doi/full/10.1002/oby.24126

33. ​ https://onlinelibrary.wiley.com/doi/full/10.1111/jvim.15915

34. ​ https://trevorklee.substack.com/p/glp-1-and-gip-agonism-and-antagonism

35. ​ https://www.annualreviews.org/content/journals/10.1146/annurev-med-043021-014919

36. ​ https://www.boehringer-ingelheim.com/human-health/metabolic-diseases/obesity/phase-ii-clinical-trial-weight-loss-results

37. ​ https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-discontinue-development-obesity-drug-2023-06-26/

38. ​ https://x.com/DanielJDrucker/status/1673383917888348174

39. ​ https://x.com/FattyLiverA/status/1672144869886685189

40. ​ Drug release profile of a novel exenatide long-term drug delivery system (OKV-119) administered to cats

41. ​ https%253A%252F%252Fbmcvetres.biomedcentral.com%252Farticles%252F10.1186%252Fs12917-024-04051-6.html

42. ​ Is Target-Based Drug Discovery Efficient? Discovery and ‘Off-Target’ Mechanisms of All Drugs

43. ​ %252Fdoc%252Fstatistics%252Forder%252F2023-sadri.pdf.html

44. ​ Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicenter, randomized, dose-response, phase 2 study

45. ​ %252Fdoc%252Flongevity%252Fglp%252F2023-frias-2.pdf.html

46. Wikipedia Bibliography:

    1. ​ Lixisenatide

    2. ​ Edward Pratt